Death confirmed from rare and deadly 'brain-eating amoeba' in southern lake
Prisma Health Richland Hospital in Columbia publicly confirmed the death on July 22, according to a statement from the South Carolina Department of Public Health (DPH) sent to Fox News Digital.
The patient died after exposure to Naegleria fowleri, a rare amoeba that causes a life-threatening brain infection called primary amebic meningoencephalitis (PAM).
FOUR PEOPLE DEAD IN FLORIDA FROM FLESH-EATING BACTERIA FOUND IN COASTAL WATERS
"The July 2025 exposure to the organism Naegleria fowleri likely occurred at Lake Murray, but we cannot be completely certain, as this organism occurs naturally and is present in many warm water lakes, rivers and streams," the South Carolina DPH told Dox News Digital.
"Water activities like swimming or diving in warm freshwater areas, such as lakes and rivers, may increase the risk of exposure and infection."
Naegleria fowleri can be a risk when swimming in fresh water. The amoeba is most active in the months that the water temperature stays above 77F – July, August and September, the health official said.
Infection in humans is very rare, as this is the first case of Naegleria fowleri in South Carolina since 2016.
There is no increased risk to the public, as Naegleria fowleri is not transmissible person to person, according to the statement.
DANGEROUS FUNGUS COULD SPREAD TO PARTS OF US, RESEARCHERS CLAIM
"Historically, one infection does not increase the chances that another will occur in the same body of water."
Fox News Digital previously spoke with Tammy Lundstrom, chief medical officer and infectious disease specialist for Trinity Health in Michigan, about the risks of infection.
"The risk of brain-eating amoeba is very low," she said. "Fewer than 10 people in the U.S. every year get infected — but unfortunately, most cases are fatal. There are only a handful of survivors of known cases."
The death rate for Naegleria fowleri exceeds 97%, per the CDC. Warning signs to recognize
The initial symptoms of PAM usually begin about five days after exposure, but they can be noticed sooner.
Early signs usually include headache , nausea, fever and/or vomiting, the CDC's website states.
As the infection progresses, people may experience confusion, stiff neck, disorientation, hallucinations, seizures and coma.
CLICK HERE TO GET THE FOX NEWS APP
"People usually start to feel ill one to 12 days after water exposure," Lundstrom said. "Early symptoms should prompt a medical evaluation, as they are also signs of bacterial meningitis ."
Death can occur anywhere between one and 18 days of infection, at an average of five days. Prevention of infection
To prevent potentially fatal infections, South Carolina health officials said it's important to know how and when exposure could be dangerous.
"How exposure occurs is when water forcefully enters the nose," the officials told Fox News Digital. "To reduce the risk of infection from Naegleria fowleri, hold your nose shut, use nose clips, or keep your head above water, and avoid jumping or diving into fresh water."
Lundstrom reiterated that it's best to avoid immersing your head in the water when swimming in summer.
"Infection occurs when water harboring the amoeba goes up a person's nose, usually during swimming," she previously told Fox News Digital. "It is not known why some people get infected and others, even swimming companions, do not."
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Drinking contaminated water does not present a risk, and the infection does not spread from one person to another, Lundstrom added.
Because the amoeba is found in soil, the CDC also recommends avoiding stirring up the sediment at the bottom of lakes, ponds and rivers. Treatment of brain-eating amoebas
When a patient has been diagnosed with a brain-eating amoeba, treatment usually includes a variety of antifungal medications , as well as antibiotics like rifampin and azithromycin, according to Lundstrom.
Miltefosine, a newer antifungal drug, has been shown to kill Nagleria fowleri in laboratory tests and was used to treat some surviving patients, the CDC states on its website.
"However, the effect of all of these drugs on actual infected people is unknown due to the high fatality rate," Lundstrom noted.
Those who experience sudden headache, fever, stiff neck or vomiting — especially if they have recently been swimming in warm freshwater — should seek immediate medical attention , the CDC recommends.
For more Health articles, visit foxnews.com/health
Despite the infection's high fatality rate, Lundstrom emphasized the rarity of cases.
"Millions of people enjoy swimming every summer, but only a few become infected," she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
16 hours ago
- Washington Post
Radioactive wasp nests found near nuclear storage site in South Carolina
In early July, a wasp nest with a radiation level 10 times what is allowed by federal regulations was found inside the grounds of a sprawling Cold War-era nuclear site in South Carolina that today partly serves as a storage area for radioactive liquid waste. Federal officials said Friday that at least three more contaminated wasp nests were found within the 310-square-mile Savannah River Site, which encompasses an area more than four times the size of the District of Columbia.
Forbes
18 hours ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.
New York Times
a day ago
- New York Times
‘Hot Wasps' Found at Nuclear Facility in South Carolina
Four radioactive wasp nests have been discovered at a South Carolina nuclear facility, according to federal officials. The first nest, which was found by workers at the Savannah River Site early last month, was recently disclosed in a report from the Department of Energy, which owns the site. The facility, near Aiken, S.C., produced material for nuclear weapons throughout the Cold War. Three additional nests have since been discovered at the site, officials told The Times on Friday. 'The U.S. Department of Energy is managing the discovery of four wasp nests with very low levels of radioactive contamination,' Edwin Deshong, the manager of the department's Savannah River Operations Office, said in an emailed statement. 'The nests do not pose a health risk to SRS workers, the community, or the environment.' But the discovery raised questions about the extent of the environmental contamination at the site, said Timothy Mousseau, a biologist at the University of South Carolina who studies organisms and ecosystems in radioactive regions of the world, including Chernobyl, Ukraine, and Fukushima, Japan. 'This is an indicator that there are contaminants spread across this area that have not been completely encased and protected,' Dr. Mousseau said. The discovery of additional radioactive nests, he added, 'indicate that much greater effort must be made to assess the possible risks and hazards of what appears to be a significant source of radioactive pollutants.' Want all of The Times? Subscribe.
